Charlton Michael R, Pockros Paul J, Harrison Stephen A
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Hepatology. 2006 Jun;43(6):1177-86. doi: 10.1002/hep.21239.
Obesity and the metabolic syndrome have hepatic manifestations, including steatosis and progression of fibrosis. In individuals with chronic hepatitis C, obesity is associated with inflammation, insulin resistance, steatosis, progression of fibrosis, and nonresponse to treatment with interferon or peginterferon alpha and ribavirin. Patients with both hepatitis C and obesity-related nonalcoholic fatty liver disease are at greater risk for more advanced liver disease. We review the mechanisms by which obesity may be associated with decreased efficacy of interferon-based therapies in individuals with chronic hepatitis C and the therapeutic strategies that may increase the effectiveness of these therapies in obese individuals.
肥胖和代谢综合征有肝脏表现，包括脂肪变性和纤维化进展。在慢性丙型肝炎患者中，肥胖与炎症、胰岛素抵抗、脂肪变性、纤维化进展以及对干扰素或聚乙二醇干扰素α和利巴韦林治疗无反应有关。丙型肝炎和肥胖相关非酒精性脂肪性肝病患者发生更严重肝病的风险更高。我们综述了肥胖可能与慢性丙型肝炎患者基于干扰素治疗疗效降低相关的机制，以及可能提高肥胖患者这些治疗有效性的治疗策略。
